Advancements in Multiple Sclerosis Treatment: Emerging Therapies Explained
https://unsplash.com/photos/human-brain-toy-IHfOpAzzjHM
Curious about what’s changing the landscape of MS treatment?
The MS therapy pipeline has long been dominated by relapsing disease treatments that fall short for progressive MS. But now after decades of limited progress, promising drugs are finally hitting the market that show real potential in treating progressive forms of the disease. With nearly 1 million Americans now living with MS, these advances couldn’t come soon enough.
Here’s what’s exciting:
Therapies that work on the root causes of MS progression in brand new ways. From brain-penetrant drugs to engineered immune cells, these breakthrough treatments are offering new hope to patients who have had few effective options until now.
What you’ll learn:
- Breakthrough BTK Inhibitors Opening New Doors
- Cell Therapy Revolution: CAR-T in MS
- Advanced Biomarkers Shaping Treatment Choices
- Impact on Progressive MS Treatment
Breakthrough BTK Inhibitors Opening New Doors
The biggest MS therapy breakthrough in the pipeline right now? BTK inhibitors.
Here’s why this matters: Unlike existing MS drugs that target peripheral immune activity but can’t cross the blood-brain barrier, these new medications are designed to penetrate the brain and target inflammation in the CNS.
Tolebrutinib is the first brain-penetrant BTK inhibitor to show effectiveness in trials. In the phase 3 HERCULES trial, tolebrutinib delayed disability progression by 31% compared to placebo in non-relapsing secondary progressive MS patients.
Impressive, right?
But what’s even more exciting is that this is the first treatment specifically designed for non-relapsing secondary progressive MS, which previously had no approved treatments.
The FDA has granted breakthrough therapy designation to tolebrutinib, with approval expected by September 2025. This treatment, which would be the first of its kind, specifically targets “smoldering neuroinflammation,” which is the ongoing brain inflammation that’s driving the long-term disability seen in progressive MS.
How BTK Inhibitors Work
BTK inhibitors target a protein called Bruton’s tyrosine kinase that regulates B cells and microglia, which are immune cells in the brain. Blocking BTK allows drugs like tolebrutinib to:
- Reduce damaging immune activity in the brain
- Target disease-associated microglia
- Halt ongoing neurodegeneration
- Prevent further accumulation of disability
The key to this approach is that it targets the underlying biology of MS progression and not just the symptoms.
Cell Therapy Revolution: CAR-T in MS
Want to hear about something that sounds like it’s from the future but is already happening?
CAR-T cell therapy for MS. This ultra-cutting-edge treatment, already approved for blood cancers, is showing remarkable results in early MS trials.
Here’s how it works: Doctors take a patient’s immune cells and engineer them in a lab to recognize specific cells that drive the disease, then infuse them back into the patient to halt the immune attack on the brain. It’s like giving the immune system a software update to stop it from attacking healthy brain tissue.
Recent trials at Stanford and UCSF found that KYV-101, a CAR-T therapy that targets CD19+ B cells, is both safe and effective in progressive MS patients. The treatment was well-tolerated with no serious safety issues, and importantly, the engineered cells were able to make their way to the brain and spinal fluid.
CAR-T Treatment Advances
Multiple companies are developing CAR-T therapies, including KYV-101, IMPT-514, and Eque-cel, that could potentially have durable effects with a single infusion. And by leveraging the patient’s own cells, these therapies have the potential to target and eliminate MS drivers that have thus far proven difficult to target with small molecules.
Advanced Biomarkers Shaping Treatment Choices
Here’s something most people aren’t aware of:
The way we diagnose and monitor MS is about to get a whole lot smarter. Advanced biomarkers and imaging techniques are helping doctors make better treatment decisions faster than ever.
New multiple sclerosis research has shown that a type of lesion in the brain called paramagnetic rim lesions (PRLs) can be used to predict which patients will respond best to certain treatments. In tolebrutinib trials, patients with more PRLs had even greater benefit, showing up to 54% lower risk of disability progression.
New Diagnostic Tools
The revised McDonald criteria, released in 2024, included several advances in diagnostic accuracy:
- Novel MRI markers for earlier detection
- Improved methods to measure biomarkers in cerebrospinal fluid
- Better prediction of disease progression
- More precise treatment targeting
All this means that doctors can start effective treatment sooner and choose the right therapy for each patient.
Targeting Smoldering Neuroinflammation
Curious to know what’s really driving MS progression?
It’s a term called “smoldering neuroinflammation” that refers to persistent, low-grade immune activity in the brain that can continue even when patients aren’t having relapses.
Why this is big news is that traditional MS drugs mainly target the peripheral inflammation that causes relapses. But they do little to address this ongoing brain inflammation that’s responsible for long-term disability.
This is where the BTK inhibitors like tolebrutinib come in. They are the first treatments specifically designed to target smoldering inflammation. By being able to cross the blood-brain barrier, they can:
- Modulate microglia that are associated with the disease
- Reduce ongoing chronic CNS inflammation
- Slow neurodegeneration
- Prevent disability accumulation
We’re essentially making a fundamental shift in how we think about treating progressive MS.
Impact on Progressive MS Treatment
Here’s the bottom line: All these advances are especially game-changing for progressive MS patients.
Approximately 15% of newly diagnosed patients have primary progressive MS, and 50% of relapsing-remitting MS patients progress to secondary progressive forms of the disease over time. Until recently, these patients have had few if any treatment options.
Now with BTK inhibitors showing efficacy in both secondary and primary progressive MS, and CAR-T therapies demonstrating safety and early efficacy signals, the treatment landscape for progressive MS has been completely transformed.
What this Means for Patients
The impact of these advances extends beyond just new drugs:
- Earlier intervention with more targeted therapies
- Personalized treatment based on biomarker profiles
- Improved outcomes for the progressive forms of the disease
- Hope for remission with cell-based therapies
The economic impact is significant too. Current DMTs cost between $57,202 and $92,719 per year per person. The more targeted approaches being developed now potentially offer better outcomes and less frequent dosing.
Looking Forward: The Future of MS Treatment
The pipeline for MS treatment has never been more robust. Remyelination therapies, neuroprotective agents, and combination therapies targeting multiple disease pathways are being explored.
PERSEUS trial results for tolebrutinib in primary progressive MS are expected in late 2025. That could open the door to treatment for even more people.
Taking the Next Steps
These breakthrough therapies represent more than just new treatment options. They represent a fundamental shift in how we approach MS care. For the first time in decades we have treatments that can target the underlying drivers of progression, not just manage symptoms.
The future of MS treatment is brighter than ever. With brain-penetrant drugs, engineered immune cells, and precision medicine approaches, we are moving closer to a future where MS progression can be stopped, not just slowed.
If you or someone you love is living with MS, there’s never been a more important time to be knowledgeable about your care and work with specialists who are. The MS treatment landscape is changing fast, and these breakthroughs could make all the difference.
